Barbara S. Fox, PhD, is a biotechnology executive with extensive leadership expertise starting up and building clinical-stage biotech companies. She is currently CEO of Rheos Medicines, a biopharmaceutical company developing novel medicines that modulate immune cell metabolism with an initial focus on treating patients with severe autoimmune diseases and cancer. Dr. Fox was previously CEO of Tilos Therapeutics, a company developing antibodies specific for LAP-TGFβ for the treatment of cancer, fibrosis and autoimmune disorders that was acquired by Merck in 2019. Dr. Fox has previously served as Entrepreneur-in-Residence at Partners Innovation Fund, founder and CEO of Avaxia Biologics, founder and CSO of Recovery Pharmaceuticals, VP Discovery and Immunology at ImmuLogic Pharmaceutical Corp., and Associate Professor of Rheumatology at the U. Maryland School of Medicine. Dr. Fox received her AB in chemistry from Bryn Mawr College, her PhD in chemistry from MIT and trained as a post-doc in cellular immunology at the NIH.